Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 20/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 20/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 13/20 | 0.47 |
| ▸ | HTR2C | P28335 | 3/20 | 0.43 |
| ▸ | HTR2B | P41595 | 3/20 | 0.43 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | TSPO | P30536 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29573444 | 1.00 | ADORA3 (0.47) | ADORA3ADORA1ADORA2AHTR2CHTR2B | |
| SCHEMBL23201580 | 1.00 | ADORA3 (0.47) | ADORA3ADORA1ADORA2AHTR2CHTR2B | |
| SCHEMBL15935852 | 1.00 | ADORA3 (0.47) | ADORA3ADORA1ADORA2AHTR2CHTR2B | |
| SCHEMBL26969051 | 0.88 | ADORA3 (0.40) | ADORA3ADORA1ADORA2AHTR2CHTR2B | |
| SCHEMBL15935848 | 0.88 | ADORA3 (0.40) | ADORA3ADORA1ADORA2AHTR2CHTR2B | |
| SCHEMBL12509206 | 0.88 | ADORA3 (0.40) | ADORA3ADORA1ADORA2AHTR2CHTR2B | |
| SCHEMBL29573299 | 0.85 | ADORA3 (0.50) | ADORA3ADORA1ADORA2AHTR2CHTR2B | |
| SCHEMBL29574515 | 0.82 | ADORA3 (0.40) | ADORA3ADORA1ADORA2AHTR2CHTR2B | |
| SCHEMBL29573771 | 0.82 | ADORA3 (0.61) | ADORA3ADORA1ADORA2AHTR2CHTR2B | |
| SCHEMBL29573310 | 0.81 | ADORA3 (0.54) | ADORA3ADORA1ADORA2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252823-A1 | ADENOSINE RECEPTOR AGONISTS, PARTIAL AGONISTS, AND ANTAGONISTS | SERVICES (US) | 2012-10-04 | — | — | US | disclosed |
| US-20110171130-A1 | A3 ADENOSINE RECEPTOR ANTAGONISTS AND PARTIAL AGONISTS | The United States of America, as represented by the Secretary ,Deptment of Health and HumanService (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171130-A1 | A3 ADENOSINE RECEPTOR ANTAGONISTS AND PARTIAL AGONISTS | ADORA3, ADORA2B, ADORA1 | ADORA3 1/4885ADORA1 3/4885ADORA2A 4/4885 |
| US-20120252823-A1 | ADENOSINE RECEPTOR AGONISTS, PARTIAL AGONISTS, AND ANTAGONISTS | ADORA1, ADORA3, ADORA2A | ADORA3 2/4885ADORA1 1/4885ADORA2A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.